NASDAQ, DNDN - Dendreon Corp
Dendreon Corporation (?Dendreon?, the ?Company?, ?we?, ?us?, or ?our?), a
Delaware corporation originally formed in 1992 as Activated Cell Therapy, Inc.,
is a biotechnology company focused on the discovery, development and
commercialization of novel therapeutics that harness the immune system to fight
cancer. Our goal is to develop innovative cancer treatments that significantly
improve cancer treatment options for patients. Our product portfolio includes
active cellular immunotherapy, monoclonal antibody and small molecule product
candidates to treat a wide range of cancers. Our most advanced product candidate
is Provenge? (sipuleucel-T), an active cellular immunotherapy that has completed
two Phase 3 trials for the treatment of asymptomatic, metastatic,
androgen-independent prostate cancer. ...
Read SEC Filing on NASDAQ.com »